Loading clinical trials...
Loading clinical trials...
A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis
Conditions
Interventions
MK-8189
Placebo
Locations
8
United States
CITrials ( Site 0007)
Santa Ana, California, United States
Top Medical Research ( Site 0005)
Cutler Bay, Florida, United States
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, United States
Well Pharma Medical Research, Corp. ( Site 0006)
Miami, Florida, United States
Atlanta Center for Medical Research ( Site 0004)
Atlanta, Georgia, United States
iResearch Atlanta ( Site 0009)
Decatur, Georgia, United States
Start Date
July 1, 2022
Primary Completion Date
January 10, 2023
Completion Date
January 10, 2023
Last Updated
September 25, 2024
NCT06159673
NCT07457138
NCT07033494
NCT07422857
NCT07214727
NCT06584357
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions